| |
|
|
|
|
|
Access® Digoxin
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
Access® Digoxin Calibrators
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
Access® Digoxin Zero Calibrator
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
Siemens Healthcare Diagnostics offers a panel of Therapeutic Drug Monitoring (TDM) assays that meet the majority of any laboratory’s high volume TDM testing needs. This broad panel allows the consolidation of a greater number of your high volume TDM assays onto one immunoassay platform.
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
Digoxin is a cardiac glycoside used in the treatment of congestive heart failure and supraventricular arrhythmias. It has a narrow therapeutic window of 0.8- 2.0 ng/mL with a potential fatal toxicity.
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
CC DIGOXIN CAL(1EA)
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
CC DIGOXIN RGT(500T)
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
Digitoxin is a naturally occurring cardiac glycoside that is used to treat congestive heart
failure and atrial fibrillation. Therapeutically, the major pharmacodynamic property of digitoxin
is to increase the force of myocardial contractions. It is also known to slow the ventricular
rate in cases of atrial fibrillation.
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
Digoxin is widely prescribed for the treatment of congestive heart failure and various
disturbances of cardiac rhythm. Therapeutic use of digoxin improves the strength of
myocardial contraction and results in the beneficial effects of increased cardiac
output, decreased heart size, decreased venous pressure and decreased blood
volume. Digoxin therapy also results in stabilized and slowed ventricular pulse rate.1
Studies suggest that up to 25 of all hospitalized patients treated with digoxin
experienced some degree of toxicity, and that the mortality rate among toxic patients
was more than twic
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
DigiFab™ [Digoxin Immune Fab (Ovine)] is a sterile, purified, lyophilized preparation of digoxin-immune ovine Fab (monovalent) immunoglobulin fragments. These fragments are obtained from the blood of healthy sheep immunized with a digoxin derivative, digoxin-dicarboxymethoxylamine (DDMA), a digoxin analogue which contains the functionally essential cyclopentaperhydrophenanthrene: lactone ring moiety coupled to keyhole limpet hemocyanin (KLH). The final product is prepared by isolating the immunoglobulin fraction of the ovine serum, digesting it with papain and isolating the digoxin-specific Fa
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|